Tempus AI Inc, a prominent player in the health care sector, recently became the subject of interest from ARK Invest, a well-known investment management firm. On March 12, 2026, ARK Invest’s flagship funds executed a modest purchase of Tempus AI shares, acquiring a few thousand units through its Genomic Revolution ETF. This transaction is part of a broader investment strategy that saw ARK Invest expanding its positions in several biotech and digital-payment companies while simultaneously reducing its exposure to certain semiconductor and healthcare entities.
The acquisition of Tempus AI shares underscores ARK Invest’s ongoing interest in gene-editing and precision-medicine technologies. Despite the strategic significance of this move, the trade size was relatively small compared to other holdings within the portfolio. This suggests that while Tempus AI is of interest, it is not currently a major focus within ARK Invest’s investment strategy.
As of March 12, 2026, Tempus AI Inc’s close price stood at $49.98. The company’s stock has experienced significant volatility over the past year, with a 52-week high of $104.32 recorded on October 8, 2025, and a 52-week low of $36.22 on April 8, 2025. The market capitalization of Tempus AI Inc is currently valued at $8.85 billion USD.
Financially, Tempus AI Inc presents a challenging picture, with a price-to-earnings ratio of -35.19. This negative ratio indicates that the company is not currently generating profits, which may be a point of concern for investors. However, the recent interest from ARK Invest could signal potential growth opportunities in the future, particularly in the areas of gene-editing and precision medicine, where Tempus AI is positioned.
The transaction was reported in the fund’s daily trade disclosures, and no additional commentary on Tempus AI’s performance was provided. This lack of further insight leaves investors and analysts to speculate on the potential reasons behind ARK Invest’s decision to include Tempus AI in its portfolio, despite the company’s current financial challenges.
Overall, the modest purchase by ARK Invest highlights the strategic interest in Tempus AI’s focus areas, even as the company navigates its financial hurdles. Investors will likely be watching closely to see how Tempus AI leverages its position in the rapidly evolving health care sector, particularly in the realms of genomics and precision medicine.
